LTMCI Clinical Workshop 5.4

How Do Clinicians Transit From Bench to Bedside?Based on a Study of Epigenetic Regulation of Melanoma

Speaker: Zhong Guo

Reporter: Yongjian Zhou, Yonghui Nie

Translator: Zhongxiao Wang

Background

The studies of tumor diagnosis and tumor makers for prognosis are the most concerned by medical professors, and the methodologies for those studies are fundamentally similar. But the questions we focus here are the methods of conducting proper scientific research design and technical route. How do we screen relative genes (looking for a needle in a haystack)? What are the current methods in use, and what are the advantages and disadvantages of these methods? After screening the genes out, how do we verify those genes?

screen-shot-2016-02-14-at-11-3Content

Dr. Guo systemically introduced the disease of malignant melanoma in clinic, and then demonstrated the study of the epigenetics in melanoma, including regulatory mechanisms of epigenetics in malignant melanoma and other skin cancers, and the verification the epigenetics as a novel biomarker of melanoma. In addition, epigenetics has a potential to be a new target of treating melanoma, and the regulation of epigenetics is the key point of preventing the development of skin cancers.

Summary

During the class discussion, the students enthusiastically communicated with Dr. Guo based on their clinical practice and the problems they encountered in clinical research, the major focus was how to identify problems in the clinic, and then make proper research design to reveal the relative molecular mechanism from biology methods. Dr. Guo showed how to skillfully merge the latest scientific concepts and methods into our daily clinical practice, and provided a new approach to explore new methods to prevent and treat cancer and other diseases.

img_2953 

img_2951